Contineum Therapeutics, Inc.
Clinical-stage biopharma developing oral small molecule therapies for NI&I conditions.
CTNM | US
Overview
Corporate Details
- ISIN(s):
- US21217B1008
- LEI:
- Country:
- United States of America
- Address:
- 3565 GENERAL ATOMICS COURT, SUITE 200, 92121 SAN DIEGO
- Website:
- https://www.contineum-tx.com/
- Sector:
- Manufacturing
Description
Contineum Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel, oral small molecule therapies for conditions at the intersection of neurology, inflammation, and immunology (NI&I). The company focuses on pioneering treatments that target clinically validated biological pathways to address diseases with limited therapeutic options. Its pipeline features multiple drug candidates in clinical trials. Key programs include a lysophosphatidic acid 1 (LPA1) receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PrMS), and an M1 muscarinic receptor (M1R) antagonist for major depressive disorder (MDD), developed in collaboration with Janssen Pharmaceutica NV.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Contineum Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Contineum Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Contineum Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
